Get notified of page updates

Search Results: Treatment + Prostate Cancer + Hormone Sensitive (0 results)

New Search
Additional Results on Clinicaltrials.gov Treatment + Prostate Cancer + Hormone Sensitive + adt
67 results
Clinical Trial Official Title
NCT04019964 Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
NCT05050084 Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NCT04363164 Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
NCT05568550 Pembro With Radiation With or Without Olaparib
NCT06130995 Relugolix + Enzalutamide Study in High-Risk Prostate Cancer
NCT04705038 Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments
NCT05939414 An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
NCT05700903 Contributions to Hypertension With Androgen Deprivation Therapy
NCT03456843 Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer
NCT06397703 ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
NCT06171269 Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life
NCT05155046 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
NCT06500169 Golf Recreational Exercise for Enhanced Survivorship in Prostate Cancer Survivors
NCT05498272 Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
NCT05869682 Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy
NCT06636682 FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
NCT05726292 A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
NCT04787744 Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
NCT06574880 STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer
NCT04175431 Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
NCT06392295 PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer
NCT04734730 Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
NCT04188535 Serial MRI Scans During Radiation Therapy
NCT05838716 High-Dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients
NCT06205316 SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
NCT04513717 Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NCT06059118 Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
NCT06111313 The University of Miami Adapt (UAdapt) Trial
NCT05790213 Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation
NCT05946213 Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NCT06039371 Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
NCT06563388 Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
NCT04947254 Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
NCT06274047 PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
NCT04633252 M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer
NCT05169970 A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer
NCT05765500 RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
NCT06392841 Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations
NCT05915442 Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer
NCT06499870 Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
NCT05053152 Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
NCT04465500 EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer
NCT06244004 FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
NCT04349501 Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI)
NCT05628363 Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer
NCT06734130 Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
NCT02997709 Collection and Measurement of Biomarkers in Prostate Cancer Radiotherapy Patients
NCT06150417 MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
NCT06044857 PSMA PET Response Guided SabR in High Risk Pca
NCT06378866 Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial
NCT06111781 The SUGAR Study; SBRT and Relugolix) for Prostate Cancer
NCT04725903 Proton Radiation Therapy for the Treatment of Patients with High Risk Prostate Cancer
NCT05477823 Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer
NCT02040610 Hypofractionated Image Guided Proton Therapy for Low andIntermediate Risk Prostate Cancer
NCT06369610 Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer
NCT04775355 Study to Detect Changes in Urinary and Gut Microbiome During Androgen Deprivation Therapy and Radiation Therapy in Patients With Prostate Cancer
NCT06528210 Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
NCT06617481 PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence
NCT06212583 High-Risk Metachronous Oligometastatic Prostate Cancer Trial
NCT06235697 Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
NCT06330805 Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer
NCT05361798 T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy
NCT06305598 Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
NCT04402151 Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
NCT04253483 Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer
NCT04423211 Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
NCT06347705 A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer

Sponsored By